Skip to content
AnalystLens

Cencora, Inc. 8-K Report, Regulation FD Disclosure (Feb 18, 2026)

Reports
Regulation FD·Other Events·Exhibits & Filings
Filing Date
Filed February 18, 2026
Period End
February 17, 2026
Security
COR
In the record · 2016–202610-K1010-Q338-K184

COR filed 10 annual reports (10-K), 33 quarterly reports (10-Q) and 184 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Mar ’19Mar ’19
  2. Deal closed8-K · Jun ’21Jun ’21
  3. Leadership change8-K · Jan ’23Jan ’23
  4. Material agreement8-K · Feb ’25Feb ’25

01—Abstract

Summary

Summary of the 8-K filed February 18, 2026. Cited figures are marked; the original filing is the authoritative source.

Cencora (COR) announced on February 18, 2026 a definitive agreement to merge its animal health business, MWI Animal Health, with Covetrus, Inc. The deal values MWI at an enterprise value of $3.5 billiona.

At closing, Cencora would receive $1.25 billionb in upfront cash, $800 million in perpetual payment-in-kind preferred units, and $1.45 billion in common units of CVET TopCo, LP, the indirect parent of Covetrus. The company expects to hold approximately 34.3% of the combined entity's ownership. For investors, the transaction converts a wholly owned asset into a cash-plus-minority-stake position, and the company states the enterprise value exceeds MWI's book value.

The filing signals a strategic portfolio shift: Cencora is exiting majority control of animal health to concentrate capital on its core pharmaceutical distribution and solutions priorities. The $1.25 billionc cash component provides near-term liquidity, while the $800 million preferred units and the 34.3% common stake carry execution and valuation risk tied to the combined company's performance, which is not controlled by Cencora. Cencora also reaffirmed its fiscal 2026 guidance, but that guidance does not assume the transaction closes before the fiscal year ends September 30, 2026.

Closing is subject to customary conditions, including required regulatory approvals, so timing and terms remain uncertain. The filing's forward-looking statement disclaimers flag risks including failure to obtain approvals, failure to realize synergies, and business disruption. Investors should monitor regulatory progress, the accounting treatment and fair value of the retained equity and preferred interests, and any updated guidance once the deal's expected timeline is clearer.

02—Key points

Key Highlights

  1. Cencora will merge MWI Animal Health with Covetrus at a $3.5 billion enterprise value, which the company says exceeds MWI's book value.
  2. Upfront consideration includes $1.25 billion in cash at closing, providing near-term liquidity.
  3. Cencora receives $800 million in perpetual payment-in-kind preferred units and $1.45 billion in common units of CVET TopCo, LP.
  4. Post-closing, Cencora expects roughly 34.3% non-controlling ownership of the combined animal health company.
  5. Cencora reaffirmed fiscal 2026 financial guidance, which does not contemplate closing within fiscal 2026 (ending September 30, 2026).
  6. Closing requires customary conditions and regulatory approvals, so timing and terms are not assured.
  7. Guggenheim Securities is lead financial advisor to Cencora, with Morgan Stanley as additional advisor and Freshfields as legal advisor.

03—Questions

Frequently Asked Questions

  1. How much cash will Cencora receive from the MWI and Covetrus merger?

    Cencora will receive $1.25 billion in upfront cash proceeds at closing. The total consideration also includes $800 million in perpetual payment-in-kind preferred units and $1.45 billion in common units of the combined company.

  2. What ownership stake will Cencora retain in the combined company?

    Cencora expects to hold approximately 34.3% of CVET TopCo, LP, the indirect parent of Covetrus, as a non-controlling common equity holder.

  3. Does the transaction affect Cencora's fiscal 2026 guidance?

    Cencora reaffirmed its fiscal 2026 guidance. The guidance does not currently assume the transaction closes before the fiscal year ending September 30, 2026.

  4. What could prevent the transaction from closing?

    Closing is subject to customary conditions, including receipt of required regulatory approvals. The forward-looking statements also cite risks such as failure to obtain approvals on the expected schedule, inability to achieve expected synergies, and business disruption.

  5. Why is Cencora doing this transaction?

    Cencora says the transaction positions MWI with a partner strategically focused on animal health and allows Cencora to further invest in its key growth priorities in its core pharmaceutical solutions business.

04—Continue

← View all 8-K filings